P1.131. Total Neoadjuvant Therapy for Lymph Node-Positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction, Phase-II Multicentre Randomized Controlled Trial Protocol

Clicks: 19
ID: 326146
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #315 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Oncology/Radiation Therapy Background Neoadjuvant chemoradiotherapy (nCRT) and perioperative chemotherapy both form standard treatment for locally advanced oesophageal adenocarcinoma. By combining both therapies as Total Neoadjuvant Therapy (TNT), the local effect of nCRT and the systemic effect of chemotherapy could potentially lead to better disease control. Methods The TNT-OES-2 trial is a phase-II multicentre randomized controlled trial which combines neoadjuvant chemoradiotherapy (CROSS: 41.4 Gy + carboplatin/paclitaxel) and neoadjuvant chemotherapy (FLOT: 5-FU, Leucovorin, Oxaliplatin, Docetaxel, 4 cycles) in patients with lymph-node positive adenocarcinoma of the oesophagus or oesophagogastric junction. In total, 216 patients will be randomized in a 1:1 ratio to either arm A: TNT FLOT-CROSS or arm B: TNT CROSS-FLOT, in 11 specialised centers in the Netherlands. The primary endpoint is progression free survival at two years after randomization. Secondary objectives are feasibility, overall survival, toxicity, postoperative morbidity and mortality and quality of life. Conclusion The TNT-OES-2 trial compares TNT FLOT-CROSS with TNT CROSS-FLOT. If TNT shows promising results, the superior sequence will be examined in a consecutive phase III trial.
Reference Key
openalex_W7203995510 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Esmeede Bruijn, Charlène van der Zijden, Bas van Wijnhoven, Joost Nuyttens, Sjoerd Lagarde, Bianca Mostert
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.279
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.279/70761224/doag077.279.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.